top of page

Zapaq (d.b.a CoMentis)

Oklahoma City, OK


The Company is engaged in the development of small-molecule drugs that treat neurovascular disorders.  The Company’s primary focus is on the development of aspartic protease inhibitors, including beta secretase inhibitors, for slowing the progression of Alzheimer’s disease (the “BACE Program”).  These development programs were acquired when Zapaq merged with Athenagen to form Comentis. Beta secretase is an enzyme in the central nervous system critically involved in the pathogenesis of Alzheimer’s disease.  

In May 2008, the Company entered into a collaboration agreement with Astellas Pharma, Inc. to develop and commercialize its proprietary beta secretase-1 inhibitor and other products from the Company’s BACE program.

(Click to return to the previous page)

bottom of page